The MPA (Medroxy Progesterone Acetate) is the progesterone derivative, which is active by oral as well as parenteral routes of the administration.
The MPA (Medroxy Progesterone Acetate) is the progesterone derivative, which is active by oral as well as parenteral routes of the administration. It is white or off-white colored, odorless crystalline powder, which is stable in air, and melting at 200-210. It is easily soluble in chloroform, sparingly soluble in methanol and alcohol, soluble in dioxane and acetone, somewhat soluble in ether, as well as insoluble in water.
DEVERY 10 is structurally associated to progesterone. It is safe & very effective. It has no effect on the HDL-C levels.
DEVIRY 10 is effective in the following menstrual disorders:
Dysfunctional Uterine Bleeding
Postponement of Menstruation
Secondary Amenorrhea, having diagnostic evaluation and endogenous estrogen status Secondary Amenorrhea, having with adequate estrogen
Secondary Amenorrhea, having inadequate estrogen
Dosage & Administration
Here is the dosage administration of DEVIRY 10 in different menstrual disorders:
a) Dysfunctional Uterine Bleeding: For the heavy bleeding, the DEVIRY 10 should be given three times a day for first 7 days, two times a day for next 7 days, and once daily for next 7 days. DEVIRY 10 should be prescribed once daily from 16th-25th day in next 2 cycles. In the gentle to moderate bleeding, the DEVIRY 10 should be given once daily from 1st-14th day of first cycle and once daily from 16th -25th day within next 2 cycles.
b) Secondary Amenorrhea for the diagnostic evaluation of the endogenous estrogen condition: In this condition, the DEVIRY 10 should be given 2 times a day for 5 days. Withdrawal bleeding specifies adequate estrogenisation. In the secondary Amenorrhea with sufficient estrogen, DEVIRY 10 should be given cyclically from days 16 – 25 for the six months; and then stopped the patient and re-evaluated. In the secondary Amenorrhea with insufficient estrogen, Conjugated estrogens of 0.625 mg should be given from days 1-25 and the DEVIRY 10 on days 16-25, pursued by five days. This treatment must be continued for about 4 to 6 months.
c) Endometriosis: In Endometriosis, the DEVIRY 10 should be given once daily up to 5 daily for 3 to 4 months pursued by the clinical evaluation. It can be continued for additional 3 months if required.
d) Postponement of Menstruation: In postponement of menstruation, the treatment should be started 7 days prior to the expected date of menses. It should be given every day till the delay is required. Higher dose is needed if the treatment is begun under 7 days prior to expected date of menses.
DEVIRY 10 is usually well tolerated though, can result into effects like change in appetite, gastrointestinal disturbances, fluid retention, weight gain, skin reactions like acne, chloasma, or melasma, fatigue, drowsiness, mental depression, headache, fever, and so on.
DEVIRY 10 should be used with caution in the patients having renal, cardiovascular, or hepatic impairment, asthma, epilepsy, diabetes mellitus, migraine, and any condition that can be aggravated by the fluid retention.
Each DEVIRY tablet contains:
Medroxy Progesterone 10 mg